Business Combinations (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 05, 2020	Jun. 30, 2019	Jul. 05, 2020	Jun. 30, 2019	Dec. 29, 2019	Jan. 03, 2016	Apr. 05, 2020	Mar. 31, 2019	Dec. 30, 2018
Business Acquisition [Line Items]
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions			1 year
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 21,100,000		$ 21,100,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	13,726,000	$ 34,261,000	$ 13,726,000	$ 34,261,000	$ 35,481,000		$ 22,777,000	$ 34,349,000	$ 69,661,000
Business Combination, Contingent Consideration Arrangements, Maximum Period			2 years 6 months
Business Combination, Contingent Consideration Arrangements, Weighted Average Period			11 months
Total transaction costs	(5,200,000)	(3,300,000)	$ (7,100,000)	(5,100,000)
Business Combination, Contingent Consideration Arrangements, Description			Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Goodwill	3,107,373,000		$ 3,107,373,000		3,111,227,000
Business Combination, Contingent Consideration, Liability, Current	11,200,000		11,200,000		20,800,000
Business Combination, Contingent Consideration, Liability, Noncurrent	2,500,000		2,500,000		14,700,000
Foreign Currency Transaction Gain (Loss), before Tax	6,400,000	(4,400,000)	(3,500,000)	(4,500,000)
Interest Expense	11,586,000	17,207,000	25,251,000	33,057,000
Business Combination, Contingent Consideration, Liability	13,700,000		$ 13,700,000		35,500,000
Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			5 years
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments					(2,961,000)
Business Combination, Consideration Transferred					164,399,000
Cash Acquired					2,108,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets					15,160,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					6,278,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	45,000		$ 45,000
Cash paid to the shareholders					145,000,000
Business Combination, Consideration Transferred, Liabilities Incurred					6,446,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value					12,100,000
Goodwill	78,686,000		78,686,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	10,870,000		10,870,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					$ 164,399,000
Compensation Expense, Excluding Cost of Good and Service Sold	(5,600,000)		(6,700,000)
Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life					11 years
Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments					$ (138,000)
Business Combination, Consideration Transferred					207,391,000
Cash Acquired					12,542,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets					43,554,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					4,835,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets					100,000
Cash paid to the shareholders					219,795,000
Business Combination, Consideration Transferred, Liabilities Incurred					0
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value					0
Goodwill	73,417,000		73,417,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt					12,553,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					207,391,000
Foreign Currency Transaction Gain (Loss), before Tax		$ 2,400,000		$ 2,600,000
2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments					(302,000)
Business Combination, Consideration Transferred					45,282,000
Cash Acquired					1,334,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets					4,042,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					727,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets					481,000
Cash paid to the shareholders					45,042,000
Business Combination, Consideration Transferred, Liabilities Incurred					638,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value					634,000
Goodwill							17,005,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt					3,295,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					45,282,000
Vanadis Diagnostics AB [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						$ 93,000,000.0
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value			8,800,000			$ 56,900,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,611,301,000		1,611,301,000		1,612,407,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	$ 1,496,072,000		1,496,072,000		1,498,820,000
Core Technology [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							36,600,000
Core Technology [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							89,000,000
Core Technology [Member] | 2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					27,667,000
Customer Relationships [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 55,800,000
Customer Relationships [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					39,000,000
Customer Relationships [Member] | 2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					6,700,000
Trade Names [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					4,900,000
Trade Names [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					5,000,000
Trade Names [Member] | 2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					1,310,000
United States of America, Dollars | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			$ 4,400,000
United States of America, Dollars | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					166,500,000
United States of America, Dollars | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					433,100,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High					31,800,000
United States of America, Dollars | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					219,900,000
United States of America, Dollars | 2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments					$ 46,600,000